Selected Summaries

摘要

Stem cell therapy is considered to be a promising regenerative treatment which reverses parenchymal loss in heart failure. C-CURE (Cardiopoietic stem Cell therapy in heart failURE) is a multicentre, randomized, open, prospective trial with lineage-specified biologies that sought to primarily evaluate the feasibility and safety of autologous bone marrow-derived and cardiogenically oriented mesenchymal stem cell therapy and to look for evidence of efficacy in patients with chronic heart failure of ischaemic origin.